IdentificationGeneric Name(2S,2'S)-2,2'-(1,2-Hydrazinediylbis{methylene[(2S)-1-oxo-2,1-hexanediyl]imino})bis(6-amino-N-phenylhexanamide)DrugBank Accession NumberDB03648BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


Download MOLSDFPDBSMILESInChI


 Similar StructuresStructure for (2S,2'S)-2,2'-(1,2-Hydrazinediylbis{methylene[(2S)-1-oxo-2,1-hexanediyl]imino})bis(6-amino-N-phenylhexanamide) (DB03648)× CloseWeightAverage: 694.966 Monoisotopic: 694.489402508 Chemical FormulaC38H62N8O4SynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUFormylmethionine deformylase, putativeNot AvailablePlasmodium falciparum (isolate 3D7)AbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableClassificationNot classifiedAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyYFMXWONORHSZEM-DDOVKQMLSA-NInChIInChI=1S/C38H62N8O4/c1-3-5-17-29(35(47)45-33(23-13-15-25-39)37(49)43-31-19-9-7-10-20-31)27-41-42-28-30(18-6-4-2)36(48)46-34(24-14-16-26-40)38(50)44-32-21-11-8-12-22-32/h7-12,19-22,29-30,33-34,41-42H,3-6,13-18,23-28,39-40H2,1-2H3,(H,43,49)(H,44,50)(H,45,47)(H,46,48)/t29-,30+,33-,34-/m0/s1IUPAC Name(2S)-6-amino-2-[(2R)-2-({2-[(2S)-2-{[(1S)-5-amino-1-(phenylcarbamoyl)pentyl]carbamoyl}-2-butylethyl]hydrazin-1-yl}methyl)hexanamido]-N-phenylhexanamideSMILES[H]N([H])CCCC[C@H](N([H])C(=O)[C@@H](CCCC)CN([H])N([H])C[C@@H](CCCC)C(=O)N([H])[C@@H](CCCCN([H])[H])C(=O)N([H])C1=CC=CC=C1)C(=O)N([H])C1=CC=CC=C1ReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound5496887PubChem Substance46507126PDBe LigandBL5PDB Entries1rl4Clinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.00414 mg/mLALOGPSlogP2.29ALOGPSlogP4.13ChemaxonlogS-5.2ALOGPSpKa (Strongest Acidic)12.44ChemaxonpKa (Strongest Basic)10.5ChemaxonPhysiological Charge2ChemaxonHydrogen Acceptor Count8ChemaxonHydrogen Donor Count8ChemaxonPolar Surface Area192.5 Å2ChemaxonRotatable Bond Count27ChemaxonRefractivity223.32 m3·mol-1ChemaxonPolarizability80.3 Å3ChemaxonNumber of Rings2ChemaxonBioavailability0ChemaxonRule of FiveNoChemaxonGhose FilterNoChemaxonVeber's RuleNoChemaxonMDDR-like RuleNoChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+0.9565Blood Brain Barrier+0.6538Caco-2 permeable-0.6123P-glycoprotein substrateSubstrate0.7541P-glycoprotein inhibitor INon-inhibitor0.5586P-glycoprotein inhibitor IINon-inhibitor0.9411Renal organic cation transporterNon-inhibitor0.903CYP450 2C9 substrateNon-substrate0.8592CYP450 2D6 substrateNon-substrate0.7791CYP450 3A4 substrateNon-substrate0.6173CYP450 1A2 substrateNon-inhibitor0.8866CYP450 2C9 inhibitorNon-inhibitor0.7979CYP450 2D6 inhibitorNon-inhibitor0.8745CYP450 2C19 inhibitorNon-inhibitor0.687CYP450 3A4 inhibitorNon-inhibitor0.7845CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9301Ames testNon AMES toxic0.5412CarcinogenicityCarcinogens 0.524BiodegradationNot ready biodegradable0.9891Rat acute toxicity2.3957 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.939hERG inhibition (predictor II)Non-inhibitor0.6369  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn more


 Details1. Formylmethionine deformylase, putativeKindProteinOrganismPlasmodium falciparum (isolate 3D7)Pharmacological actionUnknownGeneral FunctionPeptide deformylase activitySpecific FunctionRemoves the formyl group from the N-terminal Met of newly synthesized proteins.Gene NameNot AvailableUniprot IDQ8I372Uniprot NamePeptide deformylaseMolecular Weight28393.87 Da×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52 